Skip to main content

What the FDA labels say about taking them together

Sevelamer and tacrolimus

Sevelamer's FDA label of November 25, 2025 names tacrolimus in its drug interactions section; the tacrolimus labels PlainMeds reads (4) do not name sevelamer.

Check it at the source: the sevelamer FDA label on DailyMed (effective November 25, 2025, Sanofi-Aventis U.S. LLC); the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.).

What does the sevelamer label say about tacrolimus?

Sevelamer label, drug interactions

For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology (12.3) ].

Source: FDA drug label (Sevelamer Carbonate), Sanofi-Aventis U.S. LLC, effective November 25, 2025 (SPL set 3abc32fe-1bfc-4759-8f7c-36095e221b06), via openFDA; the full label on DailyMed

What does the tacrolimus label say about sevelamer?

Tacrolimus's label (effective July 17, 2026) and its 3 other brand-application labels do not name sevelamer in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

35Sevelamer generic labelers
33Tacrolimus generic labelers
SevelamerTacrolimus
Labeled forn/aOrgan transplant rejection, Eczema (atopic dermatitis)
Boxed warningNoYes
Pharmacy cost (NADAC)$0.214 per tablet 800 mg tablet$0.970 per gram 0.1% ointment
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?